Tricyclic Antidepressants (TCA)

TCA-specific pharmacokinetics drive an unusually long detection window relative to other antidepressant classes. Most TCAs have elimination half-lives in the 10 to 50 hour range, with some agents (protriptyline, doxepin) extending substantially longer. Active metabolites complicate the picture: amitriptyline is metabolized to nortriptyline, imipramine to desipramine, and clomipramine to N-desmethylclomipramine — each metabolite is itself a clinically active TCA with its own half-life and its own immunoassay reactivity. Detection in a patient on amitriptyline reflects both parent and metabolite, and detection persists for days after the last dose during the active-metabolite clearance phase.

CYP2D6 and CYP2C19 genotype affect TCA metabolism substantially. Poor metabolizers accumulate parent drug to higher steady-state concentrations and have longer elimination half-lives; ultra-rapid metabolizers clear TCAs faster and may have shorter detection windows. CYP-inhibiting medications (fluoxetine, paroxetine, bupropion, ritonavir) extend detection by slowing clearance; CYP-inducing medications (rifampin, carbamazepine, phenytoin) shorten it. Concurrent SSRIs, in particular, can substantially raise TCA plasma concentrations and have been implicated in TCA toxicity in patients on combined regimens.

Dose and chronicity follow the usual pattern but with longer windows than for many other medications. A single therapeutic dose typically produces 2 to 4 days of urinary detection. Chronic therapy at antidepressant doses (often weeks to months) produces detection that extends 5 to 10 days or longer after the last dose because of accumulated tissue and metabolite reservoirs. Supratherapeutic exposures — including the overdose presentations that bring patients to emergency departments — produce both higher concentrations and longer detection.

Hepatic impairment substantially extends TCA detection because hepatic metabolism is the principal clearance pathway. Cirrhosis, hepatitis, and other hepatic conditions can multiply the elimination half-life. Renal impairment plays a smaller direct role for parent TCAs but matters for metabolite clearance. Age affects TCA pharmacokinetics through both hepatic and renal changes; geriatric patients on TCAs often show extended detection windows and are at increased risk for the cardiac, anticholinergic, and orthostatic side effects that limit TCA tolerability in older populations.

TCAs are NOT included in the SAMHSA Mandatory Guidelines panel for federal workplace drug testing, and TCA screening is not part of any DOT-regulated workplace testing program. The SAMHSA-5 panel covers marijuana, cocaine, amphetamines, opiates, and PCP — TCA is not included in the federal panel or in most non-federal workplace panels. TCA immunoassays are used principally in clinical, emergency, MAT, and forensic settings rather than for workplace screening.

Industry-standard cutoffs for commercial TCA urine immunoassays are typically 1000 ng/mL for the initial screening test. The TCA immunoassay is a class-level assay rather than agent-specific: it is calibrated to detect TCA-class compounds collectively (typically using nortriptyline or imipramine as the calibration standard) and produces a positive result when total TCA-class immunoreactive material exceeds the device cutoff. Confirmation by LC-MS/MS at SAMHSA-certified or clinical laboratories identifies the specific TCA agent or agents present and provides quantitative concentrations.

Quantitative therapeutic ranges for TCAs in serum (not urine) are well established for several agents — nortriptyline is the most studied, with a therapeutic window typically cited as 50 to 150 ng/mL — and serum monitoring is appropriate when adherence assessment, suspected toxicity, or treatment-failure investigation is the clinical question. Urine TCA immunoassays are useful for presence/absence determination but should not be used to infer serum concentrations or therapeutic adequacy. Clinical and MAT programs that need quantitative TCA monitoring should order serum levels directly rather than relying on urine immunoassay results.

TCA urinary immunoassays use the same lateral-flow competitive-binding format as other analytes on Magenta cups and dip cards on devices that include TCA coverage. The TCA antibody is raised against a representative TCA structure (typically nortriptyline or imipramine) and cross-reacts with other TCA-class compounds — this is deliberate, since the clinical question is usually "is the patient exposed to any TCA?" rather than "which specific TCA?" Read times are typically five minutes, with the standard interpretation rules: visible test line is negative, absent test line is presumptive positive at or above the cutoff, and absent control line invalidates the test.

Cross-reactivity within the TCA class is the intended behavior of the assay. Amitriptyline, nortriptyline, imipramine, desipramine, clomipramine, doxepin, and protriptyline all cross-react to varying degrees on most TCA immunoassays. The package insert lists the relative reactivity of each agent. Patients on tricyclic-structurally-related medications outside the antidepressant class — most notably, cyclobenzaprine (a tricyclic muscle relaxant structurally similar to amitriptyline), carbamazepine (an antiepileptic with a tricyclic structure), and quetiapine (an atypical antipsychotic) — have been documented as sources of TCA-class immunoassay positives. These are correctly characterized as cross-reactants rather than false positives, but they require resolution by confirmatory mass spectrometry before clinical conclusions are drawn.

TCAs are also a documented source of cross-reactivity on other immunoassay panels. The tricyclic structure produces occasional false positives on certain LSD immunoassays and has been reported on some PCP immunoassays. Programs that screen for LSD, PCP, or other analytes in populations with high TCA prescribing prevalence should review the package inserts for the specific devices in use and incorporate this cross-reactivity context into Medical Review Officer review of any presumptive positives in TCA-treated patients.

Confirmation testing by LC-MS/MS is the laboratory standard for any presumptive positive TCA screen and is essential when the clinical context requires agent-level identification. The confirmatory test identifies the specific TCA agent or agents present, quantifies parent and metabolite concentrations, and distinguishes TCA-class cross-reactants (cyclobenzaprine, carbamazepine, quetiapine) from true TCA exposure. For overdose triage in the emergency department, the immunoassay result is used immediately for clinical decision-making; confirmation follows for documentation and medico-legal purposes.

Specimen validity testing accompanies TCA screens on Magenta multi-panel devices that include adulterant pads. Because TCA-screening populations frequently include patients with significant medical comorbidities — overdose presentations, MAT patients on multiple medications, forensic cases with complex histories — programs should anticipate that some specimens will fall outside normal validity parameters for legitimate medical reasons and should structure recollection and review procedures accordingly under the program's chain-of-custody policy.